Cargando…

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma

INTRODUCTION: The glioblastoma (GBM) immune microenvironment is highly suppressive as it targets and hinders multiple components of the immune system. Checkpoint blockade (CB) is being evaluated for GBM patients. However, biomarker analyses suggest that CB monotherapy may be effective only in a smal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garzon-Muvdi, Tomas, Theodros, Debebe, Luksik, Andrew S., Maxwell, Russell, Kim, Eileen, Jackson, Christopher M., Belcaid, Zineb, Ganguly, Sudipto, Tyler, Betty, Brem, Henry, Pardoll, Drew M., Lim, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945499/ https://www.ncbi.nlm.nih.gov/pubmed/29755681 http://dx.doi.org/10.18632/oncotarget.25061

Ejemplares similares

Optimizing the delivery of chemotherapy in the setting of immunotherapy in a preclinical glioblastoma model
por: Mathios, Dimitrios, et al.
Publicado: (2015)

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system
por: Maxwell, Russell, et al.
Publicado: (2018)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira, et al.
Publicado: (2015)

High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy
por: Theodros, Debebe, et al.
Publicado: (2020)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Basis for Immunotherapy for Treatment of Meningiomas
por: Garzon-Muvdi, Tomas, et al.
Publicado: (2020)

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
por: Belcaid, Zineb, et al.
Publicado: (2014)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
por: Zhu, Ping, et al.
Publicado: (2023)

Immunotherapy earns its spot in the ranks of cancer therapy
por: Pardoll, Drew, et al.
Publicado: (2012)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
por: Traylor, Jeffrey I., et al.
Publicado: (2021)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
por: Srivastava, Siddhartha, et al.
Publicado: (2019)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
por: Mohan, Suyash, et al.
Publicado: (2021)

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy
por: Heugenhauser, Johanna, et al.
Publicado: (2022)

Utilization of the Nasoseptal Flap for Repair of Cerebrospinal Fluid Leak after Endoscopic Endonasal Approach for Resection of Pituitary Tumors
por: Kessler, Remi A., et al.
Publicado: (2019)

Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment against Glioblastoma
por: Cuccarini, Valeria, et al.
Publicado: (2019)

Combination immunotherapy: Where do we go from here?
por: Overacre, Abigail E., et al.
Publicado: (2015)

An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma
por: Storey, Kathleen M., et al.
Publicado: (2021)

Co‐delivery of dendritic cell vaccine and anti‐PD‐1 antibody with cryomicroneedles for combinational immunotherapy
por: Chang, Hao, et al.
Publicado: (2022)

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
por: Choi, John, et al.
Publicado: (2021)

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)

Immunotherapy Resistance in Glioblastoma
por: Wang, Elaina J., et al.
Publicado: (2021)

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
por: Sun, Nai-Yun, et al.
Publicado: (2019)

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
por: Yang, Fan, et al.
Publicado: (2021)

Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
por: Adhikaree, Jason, et al.
Publicado: (2020)

Mechanisms regulating PD-L1 expression on tumor and immune cells
por: Chen, Shuming, et al.
Publicado: (2019)

PGE(2) Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma
por: Nava, Sara, et al.
Publicado: (2020)

Helminth egg derivatives as proregenerative immunotherapies
por: Maestas, David R., et al.
Publicado: (2023)

Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination
por: Ben-Akiva, Elana, et al.
Publicado: (2023)

Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy
por: Mangraviti, Antonella, et al.
Publicado: (2015)

Metastatic high-grade meningioma: A case report and review of risk factors for metastasis
por: Bailey, Destiny D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gcausllahsn93qtn3dpjhgsiqe